Sergio Iannazzo

623 total citations
75 papers, 455 citations indexed

About

Sergio Iannazzo is a scholar working on Pulmonary and Respiratory Medicine, Economics and Econometrics and Pathology and Forensic Medicine. According to data from OpenAlex, Sergio Iannazzo has authored 75 papers receiving a total of 455 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 16 papers in Economics and Econometrics and 14 papers in Pathology and Forensic Medicine. Recurrent topics in Sergio Iannazzo's work include Health Systems, Economic Evaluations, Quality of Life (13 papers), Multiple Sclerosis Research Studies (9 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Sergio Iannazzo is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (13 papers), Multiple Sclerosis Research Studies (9 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Sergio Iannazzo collaborates with scholars based in Italy, United States and United Kingdom. Sergio Iannazzo's co-authors include Lorenzo Pradelli, Roberto W. Dal Negro, Silvia Chiroli, Silvia Tognella, Paola Turco, Mario Eandi, Edoardo Mannucci, LG Mantovani, Paolo Angelo Cortesi and Claudio Micheletto and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Annals of the Rheumatic Diseases.

In The Last Decade

Sergio Iannazzo

66 papers receiving 442 citations

Peers

Sergio Iannazzo
Richard Phoon Australia
Ajay Dhaygude United Kingdom
Dominick Latrémouille-Viau United States
Elizabeth Li United States
Mitra Corral United States
Richard West United Kingdom
Nabeel Aslam United States
Anthony Fenton United Kingdom
Vernon J. Henderson United States
Leïla Chénine France
Richard Phoon Australia
Sergio Iannazzo
Citations per year, relative to Sergio Iannazzo Sergio Iannazzo (= 1×) peers Richard Phoon

Countries citing papers authored by Sergio Iannazzo

Since Specialization
Citations

This map shows the geographic impact of Sergio Iannazzo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sergio Iannazzo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sergio Iannazzo more than expected).

Fields of papers citing papers by Sergio Iannazzo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sergio Iannazzo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sergio Iannazzo. The network helps show where Sergio Iannazzo may publish in the future.

Co-authorship network of co-authors of Sergio Iannazzo

This figure shows the co-authorship network connecting the top 25 collaborators of Sergio Iannazzo. A scholar is included among the top collaborators of Sergio Iannazzo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sergio Iannazzo. Sergio Iannazzo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Iannazzo, Sergio, Maurizio Benucci, & Ennio Giulio Favalli. (2018). Tocilizumab after a first-line with anti-TNF in rheumatoid arthritis: a cost-consequence analysis in the Italian setting.. PubMed. 36(3). 479–485. 4 indexed citations
3.
Stollenwerk, Björn, Sergio Iannazzo, Ron Akehurst, et al.. (2018). A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet. PharmacoEconomics. 36(5). 603–612. 7 indexed citations
4.
Iannazzo, Sergio, et al.. (2017). Cost-Effectiveness Analysis of Empagliflozin In The Treatment Of T2d With Previous Cardiovascular Disease In Italy. Value in Health. 20(9). A480–A481. 4 indexed citations
5.
Iannazzo, Sergio, et al.. (2017). Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies. PharmacoEconomics. 36(2). 189–204. 26 indexed citations
6.
Iannazzo, Sergio, Maurizio Benucci, & Ennio Giulio Favalli. (2017). Tocilizumab after A First-Line with Anti-Tnf in Rheumatoid Arthritis: A Cost-Consequence Analysis in the Italian Setting. Value in Health. 20(9). A533–A533. 3 indexed citations
7.
Negro, Roberto W. Dal, et al.. (2016). Cost of persistent asthma in Italy. Multidisciplinary Respiratory Medicine. 11(1). 44–44. 15 indexed citations
8.
Stollenwerk, Björn, Sergio Iannazzo, Ron Akehurst, et al.. (2016). Assessing The Cost-Utility of Etelcalcetide: A Markov Model. Value in Health. 19(7). A519–A519. 2 indexed citations
9.
Negro, Roberto W. Dal, et al.. (2016). Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/ Formoterol 100/6 μg b.i.d.: a 12-week cost analysis in mild-to-moderate asthma. Multidisciplinary Respiratory Medicine. 11(1). 20–20. 3 indexed citations
10.
Iannazzo, Sergio, Lisa J. McGarry, & Silvia Chiroli. (2015). Cost-Effectiveness Analysis of Ponatinib In The Treatment of Chronic-Phase Chronic Myeloid Leukemia (Cp-Cml) In Sweden. Value in Health. 18(7). A668–A668. 2 indexed citations
11.
Paolicelli, Damiano, Sergio Iannazzo, Martina D’Onghia, et al.. (2015). The Cost of Patients With Relapsing-Remitting Multiple Sclerosis Who Develop Neutralizing Antibodies While Treated With Interferon Beta. Value in Health. 18(7). A754–A754. 1 indexed citations
12.
Furneri, Gianluca, Chiara Marchesi, Sergio Iannazzo, et al.. (2015). Cost-Effectiveness Analysis of Delayed-Release Dimethyl-Fumarate In The Treatment of Relapsing-Remitting Multiple Sclerosis In Italy. Value in Health. 18(7). A697–A697. 7 indexed citations
13.
Iannazzo, Sergio, et al.. (2015). Cost-Effectiveness Analysis of Peginterferon Beta-1a In Italian Relapsing Remitting Multiple Sclerosis Management. Value in Health. 18(7). A758–A758. 3 indexed citations
14.
Iannazzo, Sergio, et al.. (2014). ECONOMIC EVALUATION OF INTRAVENOUS IODINATED CONTRAST MEDIA IN ITALY. International Journal of Technology Assessment in Health Care. 30(1). 69–77. 6 indexed citations
15.
Iannazzo, Sergio, et al.. (2013). Economic Evaluation of Intravenous Iodinated Contrast Media in Italy. Value in Health. 16(7). A468–A468. 3 indexed citations
16.
Iannazzo, Sergio, et al.. (2012). PCN100 Cost Utility Analysis of Bortezomib in a Biomarker Positive Subgroup of Relapsed and Refractory Folicular Lymphoma. Value in Health. 15(7). A427–A427. 1 indexed citations
17.
Pradelli, Lorenzo, et al.. (2010). Organization and Estimated Patient-Borne Costs of Oral Anticoagulation Therapy in Italy. Applied Health Economics and Health Policy. 8(2). 119–128.
18.
Iannazzo, Sergio, et al.. (2010). Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy. The European Journal of Health Economics. 13(1). 71–80. 14 indexed citations
19.
Pradelli, Lorenzo & Sergio Iannazzo. (2009). Solifenacin in the treatment of overactive bladder syndrome in Italian patients: pharmacoeconomic evaluation. Journal of Medical Economics. 12(1). 25–35. 5 indexed citations
20.
Pradelli, Lorenzo, et al.. (2009). The Cost Effectiveness and Cost Utility of Valsartan in Chronic Heart Failure Therapy in Italy. American Journal of Cardiovascular Drugs. 9(6). 383–392. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Richard Phoon Breakdown of academic impact, for papers by Ajay Dhaygude Breakdown of academic impact, for papers by Dominick Latrémouille-Viau Breakdown of academic impact, for papers by Elizabeth Li Breakdown of academic impact, for papers by Mitra Corral Breakdown of academic impact, for papers by Richard West Breakdown of academic impact, for papers by Nabeel Aslam Breakdown of academic impact, for papers by Anthony Fenton Breakdown of academic impact, for papers by Vernon J. Henderson Breakdown of academic impact, for papers by Leïla Chénine
Rankless by CCL
2026